Today’s Top Health Care Stories: Dr. Reddy’s Labs, Jazz, and Sanofi

Dr. Reddy’s Labs, Jazz, and Sanofi could all make health care headlines this morning. Here’s why.

Feb 26, 2014 at 9:08AM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Let's take a quick look at three stocks -- Dr. Reddy's Laboratories (NYSE:RDY), Jazz Pharmaceuticals (NASDAQ:JAZZ), and Sanofi (NYSE:SNY) -- which could all loom large in health care headlines this morning.

Dr. Reddy's Labs launches injected Sumatriptan in the U.S.
First and foremost, Indian pharmaceutical company Dr. Reddy's Laboratories announced the U.S. launch of its Sumatriptan Injection USP Autoinjector System yesterday.

The product, which is injected subcutaneously, is a generic version of GlaxoSmithKline's (NYSE:GSK) Imitrex STATdose Pen, which is used to treat migraines and cluster headaches. According to year-end data from IMS Health, Imitrex STATdosePen and its generic equivalents generated $169 million in sales during the 2013 calendar year.

The news propelled Indian shares of Dr. Reddy's to an all-time high earlier today, although the effect on the company's overall sales (Dr. Reddy's reported revenue of $2.1 billion in fiscal 2013) may not be that substantial.

The company's top-selling individual drug last year was Omez, a treatment for heartburn or irritation of the esophagus caused by gastroesophageal reflux disease (GERD), which accounted for 8% of its top line. Dr. Reddy's ADR shares have climbed 36% over the past 12 months, and the stock may climb higher this morning as a result of Sumatriptan's U.S. launch.

Jazz's fourth quarter ends on a sour note
Jazz, however, is poised to open lower this morning, after it reported disappointing fourth quarter earnings yesterday after the market close.

Jazz's fourth quarter revenue rose 28% year-over-year to $235.8 million, but missed Wall Street estimates by $2 million. Its non-GAAP earnings rose 12% year-over-year to $1.72 per share, but also missed the consensus estimate by 6 cents. The company attributed its miss on the top and bottom lines to higher incentive-based compensation, foreign exchange headwinds, and a larger number of outstanding shares.

On the bright side, the company's fiscal 2014 revenue guidance of $1.1 billion to $1.16 billion exceeded analyst estimates of $1.08 billion. Its bottom line guidance of $8.00 to $8.25 per share also compared favorably to the consensus estimate of $8.07.

Sales of Xyrem, a narcolepsy treatment, rose 45% year-over-year during the fourth quarter to $164.2 million, accounting for 70% of Jazz's top line. For the full year, sales of Xyrem climbed 50% year-over-year to $569.1 million. Oppenheimer analyst Christopher Holterhoff expects the drug to eventually hit peak sales of $1 billion by 2020, indicating that the drug's sales could continue hitting new highs next year.

Shares fell 6% after hours yesterday following the earnings announcement, but the stock is still up more than 200% over the past 12 months. Analysts at Brean Capital raised their price target on Jazz from $171 to $207 this morning, indicating 18% potential upside from yesterday's closing price.

Sanofi inks a new partnership with Ardelyx
Last but not least, Sanofi signed a new agreement with Ardelyx to license the company's novel phosphate transport NaP2b inhibitor program. The program consists of a number of early stage treatments for the treatment of hyperphosphatemia (an electrolyte disturbance characterized by an abnormally high level of phosphates in the blood) caused by end stage renal disease and chronic kidney disease.

Sanofi will assume the full responsibility of developing the drug candidates, while Ardelyx will retain the option to co-promote the drugs and receive royalties on net sales if successfully approved. Sanofi's upfront payment was undisclosed, but the company will be obligated to pay various milestone payments up to $198 million to Ardelyx if certain targets are achieved.

This new partnership symbolizes a new way for Sanofi to diversify its portfolio beyond its core growth engines of diabetes and rare disease treatments, and complements its promising collaboration with Regeneron in monoclonal antibodies.

Keep your eye on this hidden gem as well
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Leo Sun has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers